The U.S. Food and Drug Administration on Friday extended for the second time its review of Amicus Therapeutics Inc.’s experimental combination therapy to treat a muscle disorder called Pompe disease.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReutersFDAsign.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-10-28 16:54:332022-10-31 11:01:01FDA extends review of Amicus muscle disorder therapy for second time
